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Purpose: The survival benefits of adjuvant androgen-deprivation therapy (ADT) in 
prostate cancer and lymph node metastasis remain unclear. We assessed the role of 
ADT in disease progression after radical prostatectomy (RP).
Materials and Methods: Of 937 patients who underwent RP, we identified 40 (4.2%) 
who had lymph node metastasis. A total of 18 received adjuvant ADT (ADT group) and 
22 were observed (observation group). Clinical progression-free survival (PFS), can-
cer-specific survival (CSS), and overall survival (OS) were compared in the 2 groups. 
Prognostic factors for clinical progression and biochemical recurrence (BCR) were 
analyzed.
Results: The 5-year PFS, CSS, and OS of the entire cohort were 75.0%, 85.0%, and 72.5%, 
respectively. In the ADT group, 6 patients (33.3%) showed clinical progression at a me-
dian 42.7 months. The 5-year PFS, CSS, and OS rates of this group were 72.2%, 83.3%, 
and 72.2%, respectively. In the observation group, 14 patients (63.6%) received salvage 
therapy owing to BCR. Nine patients (40.9%) with BCR in the observation group showed 
clinical progression at a median 43.4 months after RP. The 5-year PFS, CSS, and OS 
rates of this group were 77.2%, 86.4%, and 72.8%, respectively. In the observation group, 
the BCR rate was lower in patients with pT3a or less disease than in those with pT3b 
disease.
Conclusions: Adjuvant ADT in node-positive prostate cancer did not reduce or delay 
disease progression or improve survival. Because a substantial number of untreated 
patients with pT3a or less disease did not experience recurrence, administration of ADT 
should be initiated carefully. However, in patients with pT3b disease, adjuvant ADT 
and radiotherapy could be considered.
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INTRODUCTION
Prostate-specific antigen (PSA) screening has resulted in 
a down-staging of prostate cancer [1], with the incidence 
of nodal metastases decreasing from 20% to 40% in the 
1980s to 5% to 10% more recently [2,3]. The extent of lymph 
node dissection and the patient selection criteria might be 
other causes of these differences [4,5]. Lymph node meta-
stasis is generally regarded to be a poor prognostic in-
dicator in patients with prostate cancer [6,7]. In patients 
with nodal metastases, nodal progression develops at a me-
dian of 18 to 24 months after radical prostatectomy (RP) 
[2], with a 5 year overall survival (OS) rate of 39.5% [8]. 
Although androgen-deprivation therapy (ADT) has been 
shown to benefit patients with high-risk, localized disease 
who are undergoing radiotherapy [9-11], its role in patients 
with nodal metastases after RP is unclear. Although imme-
diate adjuvant ADT in patients with nodal metastasis after 
RP has been found to improve OS and progression-free sur-
vival (PFS) [10,12], controversy remains about the treat-
ment effect of adjuvant ADT on survival. Furthermore, the 
appropriate timing and duration of adjuvant ADT remain Korean J Urol 2011;52:741-745
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TABLE 1. Patient characteristics 
ADT 
group
Observation 
group
p-value
No. of patients
Age (yr)
Preoperative PSA (ng/ml)
Surgical Gleason score (%)
    6
    7
    8-10
Pathological stage (%)
    T2
    T3a
    T3b
No. of positive lymph 
  nodes (%)
    1
    2
    3 or more
Positive surgical 
  margins (%)
18
63.7±5.8
  33.6±33.5
-
  3 (16.7)
15 (83.3)
-
  4 (22.2)
14 (77.8)
12 (66.7)
  4 (22.2)
  2 (11.1)
12 (66.7)
22
64.3±6.5
  35.7±43.5
2 (9.1)
  4 (18.2)
16 (72.7)
2 (9.1)
  7 (31.8)
13 (59.1)
13 (59.1)
2 (9.1)
  7 (31.8)
15 (68.2)
0.770
0.871
0.263
0.370
0.211
0.592
ADT: androgen-deprivation therapy, PSA: prostate-specific anti-
gen
to be clarified. 
In addition, because long-term ADT has the potential for 
serious side effects, including osteoporosis, cardiovascular 
disease, diabetes, and mood disorder [13], the initiation 
and maintenance of ADT should be considered carefully. 
We therefore assessed the role of adjuvant ADT for 2 years 
on disease progression after RP for node-positive prostate 
cancer.
MATERIALS AND METHODS
Of 937 patients who underwent RP performed by a single 
surgeon between 1990 and 2008, we identified 40 (4.2%) 
who had lymph node metastasis. Of these 40 patients, 18 
received adjuvant ADT for 2 years (ADT group), whereas 
the remaining 22 were followed without therapy (observat-
ion group). Forms of ADT included bilateral orchiectomy 
in 2 patients and maximal androgen blockade including 
LHRH agonist injection and oral antiandrogens in the re-
maining 16 patients.
Postoperatively, PSA was measured every 3 months for 
the first 2 years, and every 6 months thereafter, unless re-
currence was suspected. In all patients, PSA was un-
detectable at the first hospital visit except in 3 patients in 
the observation group with PSA levels of 13.6 ng/ml, 23.4 
ng/ml, and 20.6 ng/ml. Radiographic evaluation included 
abdominopelvis computed tomography (CT) or pelvic mag-
netic resonance (MR) and radionuclide bone scans, which 
were performed every 6 months and when clinically 
indicated. Biochemical recurrence (BCR) after RP was de-
fined as two consecutive serum PSA concentrations ＞0.2 
ng/ml, and clinical progression was defined as local re-
currence or distant metastasis on imaging study. After 
clinical progression was detected, two patients (2/6) in the 
ADT group and three patients (3/9) in the observation 
group received radiotherapy.
Clinicopathological factors and 5 year PFS, cancer-spe-
cific survival (CSS), and OS rates were compared in the two 
groups by using chi-squared tests, Kaplan-Meier analysis, 
and the log rank test. SPSS ver. 12.0 (SPSS Inc., Chicago, 
IL, USA) was used for all statistical analyses, with a p-val-
ue ≤0.05 considered statistically significant. In the ADT 
group, predictive factors of clinical progression were eval-
uated; in the observation group, the incidence and pre-
dictive factors of BCR were analyzed. None of the patients 
in the ADT group experienced severe complications requir-
ing discontinuation of therapy. The median length of fol-
low-up after surgery was 55.7 months. 
RESULTS
At the time of RP, the mean patient age was 64.0 years and 
the mean serum PSA concentration was 34.8 ng/ml. Of the 
40 patients, 31 (77.5%) had surgical Gleason scores ≥8 and 
27 (67.5%) had tumors of pathological stage T3b. There 
were no significant differences between the ADT group and 
the observation group in age, preoperative PSA, surgical 
Gleason score, pathological stage, number of positive 
lymph nodes, or percentage with positive surgical margins 
(Table 1).
The clinical 5 year PFS, CSS, and OS rates of the entire 
patient cohort were 75.0%, 85.0%, and 72.5%, respectively. 
Six (33%) patients in the ADT group experienced clinical 
progression at a median 42.7 months. In this group, five pa-
tients died, three due to prostate cancer, making the 5 year 
PFS, CSS, and OS rates of this group 72.2%, 83.3%, and 
72.2%, respectively. In the observation group, 14 (63.6%) 
patients received salvage hormonal therapy owing to BCR, 
which was observed at a median 22.9 months after RP. The 
remaining eight (36.4%) patients did not experience BCR 
during a median follow-up of 32.3 months. Nine patients 
(9/22, 40.9%) in the observation group experienced clinical 
progression at a median 43.4 months after RP and a median 
20.5 months after salvage hormonal therapy. In this group, 
six patients died, three due to prostate cancer, making the 
5 year PFS, CSS, and OS rates 77.2%, 86.4%, and 72.8%, 
respectively. There were no significant differences be-
tween the groups in clinical progression or survival (Figs. 
1, 2). The pattern of clinical progression in the ADT group 
included three patients with bone metastases, two with 
lymph node metastases, and one with metastasis at the lo-
cal prostatectomy site; the mean PSA level of these patients 
was 19.1 ng/ml (range, 1.1 to 81.0 ng/ml). In the observation 
group, five patients had bone metastases, three had lymph 
node metastases, and one had lung metastasis; the mean 
PSA level was 42.7 ng/ml (range, 0.04 to 341 ng/ml).
Age, preoperative PSA, surgical Gleason score, number 
of positive lymph nodes, and positive surgical margin were 
not prognostic for clinical progression in the ADT group or Korean J Urol 2011;52:741-745
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FIG. 1. Clinical course of the patients. LN: lymph node, ADT: androgen deprivation therapy, CP: clinical progression, BCR: 
biochemical recurrence.
FIG. 2. Kaplan-Meier curves for clinical progression in the 
androgen-deprivation therapy (ADT) and observation groups.
TABLE 2. Factors affecting BCR in the observation group
Variable HR (95% CI) p-value
Preoperative PSA (ng/ml)
Surgical Gleason score  (6-7 vs. 8-10)
Pathological stage (≤T3a vs. T3b)
No. of positive lymph nodes (1 vs. 2 
  or more)
Surgical margins (negative vs. 
  positive)
0.99 (0.98-1.01)
2.68 (0.59-12.1)
7.04 (1.55-31.9)
1.96 (0.47-7.66)
1.13 (0.34-3.68)
0.807
0.201
0.003
0.370
0.836
BCR: biochemical recurrence, HR: hazard ratio, CI: confidence in-
terval, PSA: prostate-specific antigen
for BCR in the observation group. In the observation group, 
however, BCR developed in 12 of 13 patients (92.3%) with 
pT3b tumors and in 2 of 9 patients (22.2%) pT3a or less 
(Table 2). Of the 14 patients with pT3b disease in the ADT 
group, 6 had clinical progression at a median 42.2 months 
after RP. Of 13 patients in the observation group with pT3b 
disease, 12 received salvage hormonal therapy due to BCR 
at a median 20.6 months after RP and 6 had clinical pro-
gression at a median 22.5 months after salvage therapy.
DISCUSSION
The benefits of adjuvant ADT for patients with node-pos-
itive prostate cancer after RP are still unclear. We found 
that 6 of 18 (33.3%) ADT-treated patients experienced clin-
ical progression at a median 42.7 months, compared with 
9 of 22 (40.9%) patients in the observation group, who expe-
rienced clinical progression at a median 43.4 months, in-
dicating that adjuvant ADT in patients with node-positive 
prostate cancer did not reduce or delay disease progression. 
Moreover, there were no between-group differences in the 
5 year CSS and OS rates. Our results could be supported 
by other studies [2]. In contrast, Messing et al reported that 
immediate adjuvant ADT improved PFS, CSS, and OS in 
47 patients who received immediate ADT after RP and in 
51 patients who were observed, with ADT to be started after 
detection of distant metastases or symptomatic recur-
rences [10]. The discrepancy between these studies may be 
due to the clinicopathological characteristics of the pa-
tients included in the retrospective analyses. That is, al-
though the percentages of patients with pT3b disease and 
positive surgical margins did not differ, 77.5% of our pa-
tients had a Gleason score ≥8 compared with 12.2% in the 
previous study. Thus, our patients were at higher risk of 
recurrence although they received ADT, which may have 
resulted in more developed clinical progression than in the 
previous study. In addition, the timing and duration of ADT 
were not mentioned in the previous study [9], whereas we 
initiated ADT at a mean 4.2 months after RP and continued 
treatment for 2 years. These differences in timing and du-
ration of ADT may be associated with disease progression.
Of the 22 patients in the observation group, 8 (36.3%) did 
not develop BCR during a median follow-up of 32.3 months. 
Although nodal metastases after RP represent a poor 
pathologic characteristic, not all patients are at the same 
risk of BCR and cancer-specific death [14,15]. The pro-Korean J Urol 2011;52:741-745
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portion of patients without any adjuvant therapy not expe-
riencing BCR was reported to be 15% in a previous study 
[16]. In the current study, we were unable to identify differ-
entiating prognostic factors between the patients develop-
ing BCR and those who did not, other than the pathological 
T stage. 
Because BCR did not develop in 36.4% of patients in the 
observation group and patients with pT3a disease or less 
had a significantly lower risk of BCR, stage pT3a or less 
may indicate observation rather than initiation of ADT, 
thus reducing the adverse effects of long-term ADT. In re-
gard to the initiation of adjuvant ADT in patients with 
pT3bN+ disease after RP, we found no significant differ-
ence in clinical progression between patients with pT3b 
disease who received adjuvant ADT or salvage hormonal 
therapy. In patients with pT2-4 prostate cancer, including 
64.3% with pT3b disease, and lymph node metastasis, the 
combination of adjuvant ADT and radiotherapy improved 
CSS and OS [17]. Similarly, adjuvant ADT plus radio-
therapy in patients with node-positive prostate cancer, 
60.8% with pT3b disease, improved recurrence-free sur-
vival and CSS [18]. In patients with pT3bN+, the combina-
tion of adjuvant ADT and radiotherapy may improve dis-
ease control compared with adjuvant ADT alone. Because 
adjuvant ADT failed to demonstrate survival differences 
or delay clinical progression, the timing of salvage ADT 
may also be questioned. In failing patients, hormonal ma-
nipulation did not seem to extinguish the cancer in the en-
tire population. In this regard, ADT could be reserved until 
a measurable lesion is formed or clinical symptoms ensue.
This study had several limitations, including its retro-
spective design and inclusion of a relatively small number 
of patients with node-positive prostate cancer, thus re-
ducing the power of statistical analysis. A prospective 
randomized study based on a larger population is 
necessary. Moreover, multivariate analysis of factors af-
fecting BCR in the observation group could not be done be-
cause of the small sample size. The effect of duration of ad-
juvant ADT may have affected disease progression and pa-
tient survival. Therefore, additional studies are needed to 
clarify the effects of long-term ADT.  
CONCLUSION
Adjuvant ADT in patients with node-positive prostate can-
cer did not reduce or delay disease progression or improve 
survival. Because a substantial number of untreated pa-
tients with pT3a or less did not develop recurrence after RP, 
administration of ADT should be initiated carefully in 
these patients. However, in patients with pT3b disease, ad-
juvant ADT and radiotherapy could be considered. 
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